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Abstract
Alcohol use disorders (AUD) are a major contributor to the 
global burden of disease, and have huge societal impact. 
Some studies show that AUD patients carrying the G-allele 
of the OPRM1 variant c.118A>G respond better to naltrex-
one, resulting in reduced relapse rates compared to carriers 
of the AA genotype. Genotype-guided treatment allocation 
of these patients carrying a G-allele to naltrexone could po-
tentially improve the treatment outcome. However, cost-
effectiveness of this strategy should be investigated before 
considering clinical implementation. We, therefore, evalu-
ated costs and Quality-Adjusted Life-Years (QALYs), using a 
modelling approach, from an European perspective, of 
genotype-guided treatment allocation (G-allele carriers re-
ceiving naltrexone; AA homozygotes acamprosate or nal-
trexone) compared to standard care (random treatment al-
location to acamprosate or naltrexone), by using a Markov 
model. Genotype-guided treatment allocation resulted in 
incremental costs of EUR 66 (95% CI –28 to 149) and incre-
mental effects of 0.005 QALYs (95% CI 0.000–0.011) per pa-
tient (incremental cost-effectiveness ratio of EUR 13,350 
per QALY). Sensitivity analyses showed that the risk ratio to 
relapse after treatment allocation had the largest impact 
on the cost-effectiveness. Depending on the willingness to 
pay for a gain of one QALY, probabilities that the interven-
tion is cost-effective varies between 6 and 79%. In conclu-
sion, pharmacogenetic treatment allocation of AUD pa-
tients to naltrexone, based on OPRM1 genotype, can be a 
cost-effective strategy, and could have potential individual 
and societal benefits. However, more evidence on the im-
pact of genotype-guided treatment allocation on relapse is 
needed to substantiate these conclusions, as there is con-
tradictory evidence about the effectiveness of OPRM1 ge-
notyping. © 2018 The Author(s)
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Sluiter/Kievit/van der Wilt/Schene/
Teichert/Coenen/Schellekens
Eur Addict Res 2018;24:245–254246
DOI: 10.1159/000494127
Introduction
Alcohol use disorders (AUD) are major contributors 
to the global burden of disease, with a net contribution of 
3.8% to all global deaths and 4.6% to all global disability-
adjusted life years (Disability-Adjusted Life Years; a mea-
sure of the burden of disease) [1]. Worldwide, this cor-
responds to 2·2 million deaths and 70 billion Disability-
Adjusted Life Years lost to AUD in a year [2]. This is 
mainly caused by alcohol-induced physical adversities, 
like liver disease, pancreatitis, several types of cancer, fetal 
alcohol syndrome, and neuropsychiatric disorders [3]. 
This burden of disease comes with substantial societal 
impact. In Europe, an estimated 14.6 million people are 
affected by AUD, corresponding to a total cost of about 
62.3 billion Euros a year [4]. 
Evidence-based treatment of AUD includes psycho-
logical and pharmacological interventions [5, 6]. Naltrex-
one and acamprosate are the most effective pharmacolog-
ical interventions currently available for AUD treatment 
[5, 7]. It has been shown that naltrexone significantly re-
duces the number of drinking days and the level of alcohol 
craving [8], with a number needed to treat to prevent a 
relapse into heavy drinking of 9 [9]. Comparably, the anti-
craving drug, acamprosate, has been shown to reduce the 
risk of relapse into any drinking [10], with a number need-
ed to treat to prevent a relapse of 8 [9]. In clinical practice, 
naltrexone or acamprosate are both considered first-
choice pharmacological treatments, and are prescribed 
with similar frequencies [5, 6, 10, 11]. 
Despite their proven potential effectiveness, less than 
20% of treated AUD patients receive anti-craving medi-
cation [12]. This might be due to the side effects of nal-
trexone and acamprosate, such as nausea, headache, diz-
ziness, anxiety, and diarrhea [5, 8, 10, 13], and medica-
tion contraindications: kidney failure for both naltrexone 
and acamprosate; liver issues for naltrexone [13]. Hence, 
healthcare professionals are sometimes skeptical about 
the role of pharmacotherapy in the treatment of addic-
tive behaviors [14]. Improving patient-treatment match-
ing, by selecting those patients with higher chances of 
good response might be an important step to improve the 
implementation of pharmacotherapy and treatment out-
come for AUD. 
The genetic background of a patient is one of the fac-
tors underlying differential responses to pharmacological 
treatment (“pharmacogenetics”) [15–17]. Meta-analysis 
showed that a genetic variant (single nucleotide polymor-
phism) in the OPRM1 gene (rs1799971), resulting in a 
change of A to G at position 118, is associated with in-
creased effectiveness of naltrexone. AUD carriers of a 
 G-allele (15% of the Caucasian population [18, 19]) have 
2 times lower relapse rates compared to persons with the 
AA genotype, when treated with naltrexone [15, 20, 21]. 
Prescription of naltrexone, instead of acamprosate, for all 
AUD carriers of a G-allele could improve the overall 
treatment effectiveness, by preventing more relapses and 
therefore reducing costs associated with AUD. However, 
a recent study did not support previous findings on 
OPRM1 genotype-guided treatment allocation in AUD 
patients [22]. 
Given the substantial economic costs associated with 
AUD and relapse, systematic screening for OPRM1 gen-
otype could, however, be economically attractive, even 
when there is a small effect. However, it is unknown 
whether the potential cost-savings by potential optimiz-
ing treatment for part of the AUD population outweigh 
the screening costs of genetic testing of the whole AUD 
population. Such cost-effectiveness analyses of geno-
type-guided treatment allocation are currently lacking 
[23]. However, given the contradictory evidence con-
cerning the increased effectiveness of naltrexone in 
OPRM1 G-allele carriers compared to A-allele homozy-
gotes, it is highly relevant to evaluate at which threshold 
of increased effectiveness OPRM1 genotyping becomes 
cost-effective. 
The aims of this study are to evaluate: (1) cost-effec-
tiveness, by using a modelling approach based on existing 
data, of OPRM1 genotype-guided treatment allocation of 
naltrexone to G-allele carrying AUD patients, compared 
to random (non-genotype guided) treatment allocation 
to pharmacological treatment with naltrexone or acam-
prosate, and (2) at which threshold of added effective-
ness OPRM1 genotype screening is cost-effective, from an 
 European perspective. 
Methods
Model Structure
A Markov model was built to compare the 2 different treatment 
strategies (genotype-guided treatment allocation, versus random 
treatment). This Markov model is used to model different treat-
ment options and outcomes over time by using the probabilities 
that these events or outcomes occur within a certain time range 
(Fig. 1 for an outline of the model) [24]. This analysis applied a 
societal perspective, taking all relevant societal costs into account. 
The 2 strategies were: (1) to screen all patients for the OPRM1 
c.118A>G variant, which guided treatment allocation (G-allele 
carriers receiving naltrexone, AA homozygotes receiving random 
naltrexone or acamprosate (resembling current practice as much 
as possible)), and (2) to randomly assign treatment of naltrexone 
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or acamprosate to all patients (non-genotype guided). After the 
patients received one of the treatment options depending on the 
strategy, they had a certain chance to relapse or not. The relapse 
state was an absorption state, indicating that a patient stayed in this 
health state for the rest of the time horizon. The cycle length in 
both strategies for the risk of relapse or not was 1 month, with a 
maximum time horizon of the analysis of 12 months. The analyses 
(including sensitivity analysis) were performed in Microsoft Office 
Excel 2007. 
Parameters
The parameters used for the analyses are shown in Table 1. For 
each parameter, a summary value and uncertainty range were 
searched. The summary values were used in the base-case analysis, 
and the uncertainty ranges in the sensitivity analysis. The preva-
lence estimation of the G-allele and AA genotype was based on 
several population studies [18, 19]. The estimation of the risk of 
relapse after treatment with naltrexone or acamprosate was based 
on a recent network meta-analyses on the effectiveness of pharma-
cological interventions on AUD, performed as part of a National 
Institute of Health and Care and Excellence (NICE) guideline for 
AUD [25]. Both treatments are considered equally effective, as 
shown by the credible interval of the network meta-analyses. 
Therefore, the same relapse chance was considered for both drugs. 
The chance of no relapse was complementary to the chance of re-
lapse, counting up to 100%. 
The risk of relapse in G-allele carriers when treated with nal-
trexone was based on recent meta-analysis of the effectiveness of 
naltrexone treatment in AUD G-allele carries and persons with the 
AA genotype [15]. This risk ratio was multiplied with the general 
relapse chance with acamprosate/naltrexone to determine the re-
lapse chance in G-allele carriers treated with naltrexone. 
The utility values of the events of “relapse” and “no relapse” 
were based on the same NICE guideline for AUD [25]. A utility 
(expression of the health-related quality of life) represents the pref-
erence for a certain health state, where 1 represents perfect health 
and 0 represents death, and is used to calculate Quality-Adjusted 
Life-Years (QALYs) (see Analysis) [24, 26]. The resources used in 
case of “no relapse” (including all healthcare costs) were also based 
on this guideline, and transformed to the Dutch situation by mul-
tiplying these resources with Dutch standard cost prices [27]. The 

























Fig. 1. Structure of the Markov model. In this model, the strategy 
of OPRM1 screening was compared to no screening. In the screen-
ing strategy (1; in dark gray), alcohol-dependent patients with a 
G-allele received naltrexone, and AA homozygotes randomly re-
ceived either acamprosate or naltrexone. In the no screening strat-
egy (2; in white), treatment allocation was non-genotype guided, 
and therefore patients randomly received acamprosate or naltrex-
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Dutch addiction care (“Verslavingszorg in beeld – alcohol en 
drugs”[28]), and updated with price indices to 2015. These costs 
included all societal costs (including healthcare, non-healthcare, 
and indirect costs) associated with alcohol use [29]. The costs for 
genetic screening were based on current prices provided by the 
Department of Human Genetics of the Radboudumc Nijmegen. 
As costs of naltrexone and acamprosate are comparable, these 
were not included in the analysis. 
Analysis
At first we did a base-case analysis, where the parameters, as 
presented in Table 1, were entered into the model. This base-case 
analysis was performed with the data of the meta-analyses. A Mon-
te Carlo simulation with 5000 iterations was performed [24, 26, 
30]. In these iterations, parameter uncertainty of all parameters 
was taken into account at the same time, by randomly choosing a 
value from their distribution based on the uncertainty ranges of 
Table 1. In economic evaluations, we use beta distributions for 
probability rates and utilities, as these values can vary between 0 
and 1, lognormal distribution for risk ratios, as the confidence lim-
its values are calculated on a log-scale, and gamma distributions 
for costs, as these values are always non-negative. QALYs were 
calculated by multiplying the utility value of the health state (“re-
lapse” or “no relapse”) with the time spent in that health state [24]. 
Subsequently, for each iteration of the Monte Carlo simulation, 
an  incremental cost-effectiveness ratio (ICER) was calculated, 
based on the comparison between screening and no screening. The 
results were plotted in a cost-effectiveness plane, and were used 
to  draw a cost-effectiveness acceptability (CEA) curve, which 
shows the probability that screening is cost-effective, compared to 
no  screening, for different willingness to pay (WTP) thresholds 
[24, 26]. These WTP thresholds indicate the maximum amount of 
money society is willing to pay to gain one unit of effect (i.e., 
 QALYs). Subsequently, we did univariate sensitivity analyses to 
investigate the influence of variation per parameter within an un-
certainty range. These analyses were done to show which param-
eter mostly determines cost-effectiveness. The results of these 
analyses were summarized in a Tornado diagram (Fig. 3), which 
shows the maximum impact of the extremes of the uncertainty 
ranges on the incremental net monetary benefit (iNMB) for each 
parameter. The iNMB shows the value of screening in monetary 
terms, compared to random treatment, by re-scaling the QALY 
gain into monetary value using the amount of money society is 
willing to pay for this unit of effect. This value is calculated as: 
iNMB = WTP * incremental QALYs-incremental costs. For these 
calculations, a WTP of EUR 80,000/QALY was considered, which 
is often considered as the maximum society is willing to pay to gain 
one QALY. A positive iNMB indicates that the intervention is cost-
effective, and vice versa. 
Eventually, we performed a threshold analyses for the risk 
of relapse in G-allele carriers using naltrexone, as the study of 
 Oslin et al. [22] showed no-effect of OPRM1 genotyping. With 
this threshold analysis, the minimal added effectiveness of gen-
otype-based treatment allocation at which screening is cost-ef-
fective was determined. This was calculated by varying the rela-
tive risk ratio for relapse in the genotype-based treatment alloca-
tion between 0 and 1 and then evaluate the ICER at each risk 
ratio.
Results
The results of the simulation of the base-case shows 
that treatment allocation of naltrexone versus acampro-
sate based on OPRM1 genotyping was more expensive 
with EUR 66.22 per patient (95% CI –28 to 149), but also 
more effective with 0.005 QALYs (95% CI 0.000–0.011) 
gained per patient, compared to non-genotype guided 
treatment allocation of AUD patients (Table 2). This re-
sults in an ICER of EUR 13,349.71 (95% CI 442,000 to 
dominant) per QALY. 
The results of the simulation are presented in a cost-
effectiveness plane in Figure 2a, with corresponding 
CEA curve in Figure 2b. The curve shows the probabil-
Table 1. Parameters used for cost-effectiveness analysis in the Markov model, with corresponding references
Base-case Uncertainty ranges References
Probability of G-allele carriers in Caucasians 0.150 0.100–0.200 [18, 19]
Probability of AA homozygous in Caucasians 0.850 0.800–0.900 [18, 19]
Relapse chance with acamprosate/naltrexone treatment 0.132 0.040–0.479 [25]
No relapse chance with acamprosate/naltrexone treatment 0.868 0.521–0.960 [25]
Risk ratio to relapse when G-allele carriers treated with 
naltrexone (screening strategy) 0.508 0.273–0.943 [15]
Utility of relapse 0.540 0.390–0.670 [25]
Utility of no relapse event 0.860 0.830–0.890 [25]
Costs of successful AUD treatment (no relapse) per month EUR 82.50 EUR 40.00–125.00 [25]
Costs of failed AD treatment (relapse) per month EUR 533 EUR 333–583 [28]
Costs of OPRM1 genotyping EUR 150 EUR 100–200 Human Genetics 
Department, Radboudumc
AUD, alcohol use disorders.
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ity of cost-effectiveness for different WTP levels. At a 
WTP of EUR 0, screening has a probability of 6% be-
ing “dominant,” indicating that in 6% of the iterations 
screening resulted in increased effectiveness (increased 
QALYs) and cost savings, compared to no screening 
(south-east corner of the cost-effectiveness plane). With 
a WTP of EUR 80,000 per increased QALY, often con-
sidered as the maximum people are willing to pay for a 
QALY, screening for the genetic variant in OPRM1 and 
adjusting treatment accordingly has a probability of 75% 
of being the most cost-effective strategy, corresponding 
to 75% of the iterations lying below this threshold (rep-
resented by the line in Fig. 2a). It can also been seen in 
the CEA curve (Fig. 2b) that this probability slowly rises 
(up to maximum 79%) when the WTP becomes higher. 
Univariate Sensitivity Analysis
The results of the univariate sensitivity analyses are 
presented as a Tornado diagram in Figure 3. This diagram 
shows the effect of changing a parameter (tested ranges 
are presented behind each parameter) on the iNMB. The 
risk ratio to relapse in G-allele carriers treated with nal-
trexone has the largest effect on the iNMB, ranging from 
not cost-effective at –EUR 105 to cost-effective at EUR 
684, when changing this parameter to a lower or higher 
level than in the initial analysis. Furthermore, for all oth-
er parameter values the iNMB stays positive, ranging be-
tween about EUR 170 and 516. These positive iNMBs 
show that for each parameter value screening stays cost-
effective. 
Threshold Analysis
The results of the threshold analysis are presented in 
Figure 4. In this Figure, it can be seen that at a risk ratio 
≤0.81 screening is cost-effective with a WTP of EUR 
80,000/QALY. When the risk ratio is ≤0.25, screening 
becomes the “dominant” strategy (more QALY gain at 
lower costs) compared to no screening. 
Table 2. Costs and effects of the strategies of screening and no screening








OPRM1 screening EUR 3,610.66 (EUR 1,166–5,681) EUR 66.22 (–EUR 28 to 149) 0.714 (0.574–0.862) 0.005 (0.000–0.011)
No OPRM1 screening EUR 3,544.44 (EUR 1,024–5,629) 0.709 (0.567–0.862)
Costs and QALY’s are presented as means with 95% CI, resulting from Monte Carlo simulation with 5000 iterations. 
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Fig. 2. a, b Cost-effectiveness plane and cost-effectiveness accept-
ability (CEA) curve. Outcomes of the simulation presented in a cost-
effectiveness plane, with corresponding CEA curve. This curve 
shows that the probability OPRM1-guided treatment allocation is 
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Discussion
This is the first study investigating cost-effectiveness 
of OPRM1 genotype-guided treatment allocation of nal-
trexone in AUD patients. In our base-case analysis, as-
suming an effect of the OPRM1 genotype, we showed that 
OPRM1 screening can be cost-effective. However, these 
results need to be interpreted very carefully as recent evi-
dence did not confirm prior data on OPRM1 pharmaco-
genetics in AUD [22]. On average, the genotype strategy 
is slightly more expensive, but also slightly more effective 
compared to no genotyping strategy. This results in an 
ICER of approximately EUR 13,350 per QALY, which is 
generally considered acceptable [31]. Depending on how 
much decision makers are willing to pay for a QALY, the 
probability that OPRM1 screening is the preferred strat-
Risk ratio to relapse with naltrexone G-allele (0.27–0.94)
Utility of relapse (0.39–0.67)
Percentage of G allele carriers (0.10–0.20)
Probability to relapse with acamprosate/or naltrexone (0.08–0.20)
Costs of screening (100–200)
Utility of no relapse (0.83–0.89)
Costs of relapse (333–583)
Costs of no relapse (41–124)
–105


















Fig. 3. Tornado diagram, summarizing the results of the univariate 
sensitivity analyses. In these analyses, the presented parameter es-
timates vary within an uncertainty range (presented behind each 
parameter), to see the influence on the incremental Net Monetary 
Benefit (iNMB) for a Willingness To Pay (WTP) of EUR 80,000/
























































Fig. 4. Diagram summarizing the results of 
the threshold analyses. This figure shows 
the impact of the risk to relapse in G-allele 
carriers using naltrexone on the incremen-
tal cost-effectiveness ratio (ICER), and at 
which risk ratio screening is cost-effective 
at a Willingness To Pay (WTP) of EUR 
80,000/QALY. The solid line indicates the 
ICER for each value of the risk ratio. 
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egy ranges between 6 and 79%. The univariate sensitivity 
analysis showed that the ICER is mostly determined by 
the risk of relapse in AUD G-allele carriers treated with 
naltrexone. Threshold analysis showed that when the risk 
ratio of relapse between naltrexone in G-allele carriers 
versus A-allele homozygotes was smaller than 0.82, 
screening was cost-effective at a WTP of EUR 80,000/
QALY, and at a risk ratio smaller than 0.25 screening was 
the dominant strategy. When looking at the CI of the rel-
ative risk ratio for relapse in the G-allele carriers versus 
AA homozygotes in the meta-analysis of 0.273–0.943, 
this threshold seems reachable, but the study of Oslin et 
al. [22] could not confirm this. To give a definite answer 
on the cost-effectiveness of OPRM1 genotyping, more 
studies are needed to determine the effectiveness of nal-
trexone in AUD G-allele carriers compared to AA homo-
zygotes.
The percentage of G-allele carriers in the population 
also had a major impact on the sensitivity analysis. High-
er G-allele frequencies increase the cost-effectiveness of 
OPRM1-guided treatment allocation. In Asian popula-
tions, the percentage of G-allele carriers is much higher 
(about 60%) than in Caucasian (about 15%) and African 
populations (about 1%) [19, 32]. Cost-effectiveness of 
OPRM1 genotype-guided treatment allocation in AUD 
might therefore be more cost-effective in Asian regions, 
while less cost-effective in African regions, as compared 
to Caucasian populations [19, 33].
Finally, the cost of genotyping, which probably will de-
crease in the coming years, influenced cost-effectiveness 
[34, 35]. In our model, a price below EUR 129 per genet-
ic screening, is associated with increased effectiveness at 
lower costs (“dominant”), indicating that OPRM1 geno-
type-guided treatment allocation would be the preferred 
strategy. Importantly, cost-effectiveness will also increase 
with increasing costs related to AUD and relapse. Though 
the costs of relapse have no major impact on the cost-ef-
fectiveness, our cost estimation of about EUR 6,402 per 
year is a conservative estimation of the costs [4, 36, 37]. 
Literature on AUD-related costs is, however, scarce and 
sometimes outdated. Future data on the costs of AUD 
might shed new light on cost-effectiveness of OPRM1 
genotype-guided treatment allocation in AUD. 
Economic evaluations, like the present cost-effective-
ness analysis, are widely used to inform policy makers 
about which treatment innovations should be reimbursed 
or promoted [24, 26]. Such evaluations have become in-
creasingly important, given the rising healthcare costs 
worldwide. Information about the potential benefits of an 
innovation for prevention, diagnosis or treatment at ac-
ceptable costs is critical to keep healthcare budgets sus-
tainable. Cost-effectiveness studies of pharmacological 
interventions for AUD have shown that pharmacothera-
py for AUD is highly cost-effective [38]. Adding pharma-
cogenetic treatment allocation to the treatment algorithm 
is associated with increased costs. In this study we showed 
under which conditions this intervention could be of po-
tential societal value in the treatment of AUD patients. 
This evidence is of great value, as evidence surrounding 
the most important parameter, the increased effective-
ness of naltrexone after pharmacogenetic matching is still 
contradictory. As AUD-related costs are estimated at bil-
lions of Euros worldwide, a relative simple intervention 
with even a small effect to improve pharmacological 
treatment outcome, like genetic screening, could prevent 
tremendous harm and societal costs [4]. 
Though the potential clinical utility of genetic screen-
ing seems promising, integration of genetic services into 
clinical practice is not fully supported by all healthcare 
professionals [34]. In a recent meta-analysis, four major 
barriers for implementation of genotype-guided treat-
ment allocation were identified: lack of knowledge/skills, 
lack of infrastructure, ethical, legal and social issues, and 
lack of evidence. Barriers related to insufficient knowl-
edge and skills are most frequently cited in literature [39]. 
This warrants education and training of physicians on 
genetics and genetic testing to develop pharmacogenetic 
competencies required in clinical practice. Furthermore, 
system-level barriers (lack of access to genetic services, 
time constraints) are noted as significant impediments to 
primary-care providers integrating genetics into their 
practice [39]. Development of easy accessible genetic ser-
vices and coverage by health insurance could greatly con-
tribute to the implementation of genotype-guided treat-
ment allocation in clinical practice. Importantly, person-
alizing pharmacotherapy could impact the potential 
motivational aspects in AUD patients. This could in-
crease pharmacotherapy coverage and treatment adher-
ence in AUD patients, and therefore have a huge public 
health impact. 
Finally, barriers related to scientific evidence of ge-
netics services are identified [39]. The results of the cost-
effectiveness analysis presented here do support the 
need for further development of strategies to implement 
genotype-guided treatment allocation for AUD patients. 
In future, recommendations on genotype-guided treat-
ment allocation should be incorporated in treatment 
guidelines, including those on AUD. For example, 
OPRM1 genotype-guided treatment allocation is not 
mentioned in current guidelines [5, 6, 25, 40]. Cost-ef-
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fectiveness analyses of pharmacogenetic strategies are 
therefore urgently needed, to further optimize clinical 
practice.
Moreover, several other potential candidate genes for 
genotype-guided treatment allocation in AUD have been 
suggested. For example, potential candidates possibly re-
lated to the effectiveness of acamprosate are the DRD2, 
GABRA6, GABRB2, and GATA4 genotypes [23, 41]. If 
patient-treatment matching could be further optimized 
by adding a list of genes predictive for treatment response 
to a range of medications, cost-effectiveness could in-
crease even more. As such, future evidence on genotype-
guided treatment allocation in AUD could further opti-
mize the treatment of AUD patients.
The presented model has several assumptions that 
need to be taken into account when interpreting the re-
sults of this study. First, the risk-value used in the base-
case scenario was based on a recent meta-analysis evalu-
ating the efficacy of naltrexone in AUD G-allele carriers 
versus AA homozygotes [15]. Recent evidence did not 
confirm the conclusions of this meta-analysis [22]. Our 
findings provide an indication what added effectiveness 
in G-allele carriers minimally needs to be achieved to let 
OPRM1 screening be the preferable strategy in AUD 
treatment from a cost-effectiveness perspective. 
Next, in our study both AA homozygotes and the non-
genotyping arm received acamprosate in 50% of cases. 
There is currently no evidence that in AA homozygotes, 
acamprosate is actually better than naltrexone. Scientific 
evidence mainly focused on the association between nal-
trexone efficacy and the OPRM1 G-allele. In general, 
there appears to be no difference between acamprosate 
and naltrexone in controlling alcohol consumption, as 
shown by Jonas et al. [11] Studies on the efficacy of acam-
prosate in AA homozygotes are highly needed. To mini-
mize the risk of overestimation of cost-effectiveness, we 
applied a conservative approach assuming similar effec-
tiveness for naltrexone and acamprosate. We also wanted 
the control condition to resemble the current practice as 
much as possible, to show potential benefit compared to 
current practice. Therefore, we chose 50% exposure to 
acamprosate in the AA-homozygous group and in the 
non-genotyping arm.
In our model, treatment allocation is unchanged over 
the one-year iteration period. It has to be acknowledged 
that current treatment guidelines for AUD do not men-
tion a strict evaluation window for (pharmacological) in-
terventions, unlike for example for antidepressant medi-
cation [42]. Moreover, in clinical practice a relapse is not 
necessarily an indication that the medication is ineffec-
tive, or a common reason for medication switch. On the 
contrary, in case of relapse it cannot be ruled out that the 
medication provided is ineffective, and patients should 
better switch to other potentially more effective medica-
tions. If this were true, the current model might overesti-
mate the cost-effectiveness of pharmacogenetic treat-
ment allocation of naltrexone in AUD.
The estimated probabilities of relapse with acampro-
sate or naltrexone treatment should be interpreted care-
fully. We assumed that both drugs are equally effective. 
However, in clinical practice their effectiveness varies 
highly between patients and across studies [10, 11]. If 
acamprosate happens to be more effective than naltrex-
one, the current results overestimate the cost-effective-
ness of OPRM1 genotype-guided treatment allocation, or 
vice versa. For our effectiveness parameters, we used a 
meta-analyses from a NICE guideline, which had 2 major 
limitations [25]. First, the time horizon of the model in 
this study was 12 months. The meta-analyses on the ef-
fectiveness of naltrexone and acamprosate in AUD in-
cluded only studies with a time horizon of 3–6 months. 
Since in clinical practice naltrexone and acamprosate are 
commonly prescribed for more than 3–6 months, results 
were inferred to 1-year outcome [38]. The extrapolation 
of the data over a 12-month period, could have intro-
duced uncertainty in our model. If the effectiveness of 
naltrexone or acamprosate declines after 3 or 6 months, 
this could have led to an overestimation of our results. 
Second, in all trials used in the meta-analyses, pharmaco-
therapy was used as an adjunct to psychological therapies. 
The authors of these analyses assumed that any differ-
ences in effect were related to pharmacotherapy, as op-
posed to the psychological therapies. This assumption 
could have also led to an overestimation of our results, as 
the effects of naltrexone or acamprosate could have been 
limited. 
Also, some studies do suggest that acamprosate might 
be more effective in the long-term, compared to naltrex-
one [5]. In contrast, several other studies favor efficacy of 
naltrexone in the treatment of AUD [9, 10, 16, 43]. If the 
effectiveness of naltrexone indeed declines after 6 months, 
this could lead to an overestimation of the cost-effective-
ness in our model. In addition, it has to be taken into ac-
count that European and US-based trials in AUD are of-
ten incomparable, given the common differences in pa-
tient characteristics in these studies, including differences 
in AUD severity and medication effectiveness [10, 44]. 
However, in our sensitivity analyses, we showed that the 
probability to relapse with one of the 2 drugs has limited 
effect on our results. 
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This study focused on the return to heavy drinking as 
definition of relapse, assuming that this is most relevant 
in terms of costs of relapse. It has been suggested that na-
ltrexone is more effective in reducing the total amount of 
alcohol consumption, whereas acamprosate may be more 
effective in obtaining complete abstinence [11]. Results of 
the cost-effectiveness analysis do depend on the defini-
tion of relapse. For example, including any level of drink-
ing as outcome (instead of heavy drinking) might in-
crease or decrease the cost-effectiveness. For running 
cost-effectiveness analyses, the outcome measure should 
be comparable between both arms and should be trans-
lated into monetary costs. The only available cost esti-
mates do not specify specific drinking levels. Therefore, 
we decided to compare relapse versus abstinence, though 
this does not fully match the current evidence on the ef-
ficacy of naltrexone versus acamprosate. 
Acamprosate was chosen as an alternative for naltrex-
one in the pharmacological treatment of AUD. There are 
several other effective drugs available for AUD treatment, 
including for instance disulfiram, baclofen, and topira-
mate [13, 43]. Some studies show that disulfiram might 
be less effective, compared to naltrexone and acampro-
sate [11]. Evidence for baclofen and topiramate in AUD 
is still limited, with their use in AUD being mainly off-
label [5, 38, 45]. Moreover, pharmacotherapy is often 
combined with psychosocial interventions, which might 
influence the cost-effectiveness. In future, it may be need-
ed for additional treatment options in cost-effectiveness 
analysis as well. 
In conclusion, our cost-effectiveness analysis showed 
that genotype-guided treatment allocation of naltrexone 
in patients with AUD can be a cost-effective strategy, 
compared to the random (non-genotype guided) alloca-
tion of acamprosate or naltrexone. However, uncertainty 
surrounds the evidence for pharmacogenetic treatment 
allocation of naltrexone in AUD, and supported by our 
sensitivity analyses, more studies on the effectiveness of 
naltrexone in G-allele carriers are needed to affirm the 
cost-effectiveness of genotype-guided treatment alloca-
tion in AUD. This intervention could, however, be of po-
tential value in the treatment of AUD patients at accept-
able costs, if evidence of increased effectiveness is con-
firmed and costs of genotyping decrease.
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